应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02251 鹰瞳科技-B
耶稣受难节休市 03-28 16:08:03
16.480
-0.340
-2.02%
最高
17.100
最低
15.720
成交量
17.91万
今开
16.600
昨收
16.820
日振幅
8.20%
总市值
17.07亿
流通市值
8.80亿
总股本
1.04亿
成交额
295.72万
换手率
0.34%
流通股本
5,342万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
鹰瞳科技-B(02251)下跌6.54%,报15.72元/股
金融界 · 03-28 15:26
鹰瞳科技-B(02251)下跌6.54%,报15.72元/股
鹰瞳科技-B盘中异动 下午盘快速下挫6.53%
自选股智能写手 · 03-28 15:26
鹰瞳科技-B盘中异动 下午盘快速下挫6.53%
《公司业绩》鹰瞳科技-B(02251.HK)全年亏损收窄至1.33亿人币
阿斯达克财经 · 03-28 09:43
《公司业绩》鹰瞳科技-B(02251.HK)全年亏损收窄至1.33亿人币
鹰瞳科技(02251)发布2023年度业绩:营收增长79.5% 营收毛利双增长 视网膜AI检测量达683万人次
智通财经 · 03-27 23:51
鹰瞳科技(02251)发布2023年度业绩:营收增长79.5% 营收毛利双增长 视网膜AI检测量达683万人次
鹰瞳科技(02251)发布2023年度业绩:营收同比涨近八成 近视防控和海外业务成长迅速
智通财经 · 03-27 23:24
鹰瞳科技(02251)发布2023年度业绩:营收同比涨近八成 近视防控和海外业务成长迅速
鹰瞳科技发布2023年度业绩,营收增长79.5%,近视防控和海外业务成长迅速
格隆汇资讯 · 03-27 23:06
鹰瞳科技发布2023年度业绩,营收增长79.5%,近视防控和海外业务成长迅速
鹰瞳科技-B(02251)发布2023年度业绩 收入2.04亿元 同比增加79.46%
智通财经网 · 03-27 22:22
鹰瞳科技-B(02251)发布2023年度业绩 收入2.04亿元 同比增加79.46%
鹰瞳科技-B盘中异动 早盘快速拉升5.38%
自选股智能写手 · 03-27 10:10
鹰瞳科技-B盘中异动 早盘快速拉升5.38%
鹰瞳科技-B(02251)上涨5.3%,报16.28元/股
金融界 · 03-26 15:23
鹰瞳科技-B(02251)上涨5.3%,报16.28元/股
鹰瞳科技-B盘中异动 股价大涨5.30%报16.280港元
自选股智能写手 · 03-26 15:23
鹰瞳科技-B盘中异动 股价大涨5.30%报16.280港元
鹰瞳科技-B(02251)股价上升5.304%,现价港币$16.28
阿斯达克财经 · 03-26 15:23
鹰瞳科技-B(02251)股价上升5.304%,现价港币$16.28
鹰瞳科技-B(02251)下跌7.01%,报14.32元/股
金融界 · 03-18
鹰瞳科技-B(02251)下跌7.01%,报14.32元/股
鹰瞳科技-B盘中异动 大幅跳水7.14%
自选股智能写手 · 03-18
鹰瞳科技-B盘中异动 大幅跳水7.14%
鹰瞳科技-B(02251)股价下跌7.273%,现价港币$14.28
阿斯达克财经 · 03-18
鹰瞳科技-B(02251)股价下跌7.273%,现价港币$14.28
“AI+医药”或成英伟达GTC重头戏!产业链投资飞速发展
智通财经 · 03-18
“AI+医药”或成英伟达GTC重头戏!产业链投资飞速发展
鹰瞳科技-B(02251)股价上升8.738%,现价港币$15.68
阿斯达克财经 · 03-13
鹰瞳科技-B(02251)股价上升8.738%,现价港币$15.68
鹰瞳科技-B(02251)上涨5.27%,报15.18元/股
金融界 · 03-13
鹰瞳科技-B(02251)上涨5.27%,报15.18元/股
鹰瞳科技-B获Mialkos Tomasz Jakub增持32.72万股
新浪港股 · 03-12
鹰瞳科技-B获Mialkos Tomasz Jakub增持32.72万股
Mialkos Tomasz Jakub增持鹰瞳科技-B(02251)32.72万股 每股作价约14港元
智通财经 · 03-12
Mialkos Tomasz Jakub增持鹰瞳科技-B(02251)32.72万股 每股作价约14港元
暂无数据
公司概况
公司名称:
鹰瞳科技-B
所属市场:
SEHK
上市日期:
--
主营业务:
鹰瞳Airdoc成立于2015年9月,总部在北京,截至2020年1月底,公司在北京、上海、广州、香港设立了子公司及研发中心。 鹰瞳Airdoc是全球视网膜影像人工智能领域的领导者和先行者,公司基于视网膜影像人工智能识别的早期检测、辅助诊断及健康风险评估解决方案,通过视网膜影像、多模态数据分析以及人工智能深度学习算法,改善了慢性病传统的早期检测及诊断方式,在医疗机构和大健康场景中实现对慢性病的无创、精确、快速、高性价比且大规模的诊断及相关健康风险评估。 2020年8月,鹰瞳Airdoc糖尿病视网膜病变眼底图像辅助诊断软件获国家药监局批准上市,在同类产品中首个获得国家药监局第三类医疗器械证书,并由此展开在国内医院的使用,协助及减轻医生的医学诊断工作。为解决未满足的医疗健康需求,公司开发了人工智能视网膜影像相关的丰富产品管线,已广泛应用于社区诊所、体检中心、保险公司、验光中心及药房等场所,为用户提供疾病辅助诊断及健康风险评估
发行价格:
--
{"stockData":{"symbol":"02251","market":"HK","secType":"STK","nameCN":"鹰瞳科技-B","latestPrice":16.48,"timestamp":1711613283015,"preClose":16.82,"halted":0,"volume":179100,"delay":0,"floatShares":53417001,"shares":103568013,"eps":-1.883741,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":-0.34,"latestTime":"03-28 16:08:03","open":16.6,"high":17.1,"low":15.72,"amount":2957172,"amplitude":0.082045,"askPrice":16.54,"askSize":20000,"bidPrice":16,"bidSize":9000,"shortable":0,"etf":0,"ttmEps":-1.2137654430110218,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1636041600000,"adjPreClose":16.82,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.7094193139788251,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02251/tweets","defaultTab":"tweets","newsList":[{"id":"2422134785","title":"鹰瞳科技-B(02251)下跌6.54%,报15.72元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422134785","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422134785?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:26","pubTimestamp":1711610766,"startTime":"0","endTime":"0","summary":"3月28日,鹰瞳科技-B盘中下跌6.54%,截至15:26,报15.72元/股,成交282.03万元。北京鹰瞳科技发展股份有限公司主要业务是为慢性病的早期检测、辅助诊断及健康风险评估提供全面和多方位的人工智能解决方案,特别是在全球视网膜影像人工智能领域处于领先地位。截至2023年年报,鹰瞳科技-B营业总收入2.04亿元、净利润-1.33亿元。3月27日,2023财年年报归属股东应占溢利-1.325亿人民币,同比增长26.37%,基本每股收益-1.28人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/28152640034635.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422132645","title":"鹰瞳科技-B盘中异动 下午盘快速下挫6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422132645","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422132645?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:26","pubTimestamp":1711610762,"startTime":"0","endTime":"0","summary":"2024年03月28日下午盘15时26分,鹰瞳科技-B股票出现异动,股价大幅下挫6.53%。鹰瞳科技-B股票所在的医疗设备及用品行业中,整体跌幅为0.10%。消息层面,截至15时26分,鹰瞳科技-B股票正面舆情新闻比例33.33%。《鹰瞳科技-B发布2023年度业绩 收入2.04亿元 同比增加79.46%》资讯为影响鹰瞳科技-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328152602791d796b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328152602791d796b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422909894","title":"《公司业绩》鹰瞳科技-B(02251.HK)全年亏损收窄至1.33亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2422909894","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422909894?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:43","pubTimestamp":1711590180,"startTime":"0","endTime":"0","summary":"鹰瞳科技-B(02251.HK) 公布截至去年12月底止全年业绩,营业额2.04亿元人民币(下同),按年升79.5%。亏损收窄至1.33亿元,上年同期蚀1.8亿元;每股亏损1.28元。不派息。(gc/da)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2023/08/25中期业绩无派息2023/03/23末期业绩无派息 2022/08/25中期业绩无派息 2022/03/17末期业绩无派息 AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220216122106578_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220216122106578_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338113/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422548917","title":"鹰瞳科技(02251)发布2023年度业绩:营收增长79.5% 营收毛利双增长 视网膜AI检测量达683万人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2422548917","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422548917?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:51","pubTimestamp":1711554677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月27日,医疗AI企业鹰瞳科技公布2023年度业绩报告。报告期内,公司营收增长至2.039亿元,同比增长79.5%。2023年,医院的覆盖活跃网点数量达到了276家,同比增长527.3%;检测次数达到了24.2万,同比增长197.5%。基层医疗机构的覆盖活跃网点数达到了1,221家,同比增长1,271.9%;检测次数达到63.5万,同比增长640.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094170.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422148329","title":"鹰瞳科技(02251)发布2023年度业绩:营收同比涨近八成 近视防控和海外业务成长迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2422148329","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422148329?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:24","pubTimestamp":1711553076,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月27日,医疗AI企业鹰瞳科技公布2023年度业绩报告。报告期内,公司营收增长至2.039亿元,同比增长79.5%。2023年,鹰瞳科技通过SaMD和健康风险评估解决方案共计服务了683百万人次病例,识别出 31,459例重大阳性案例,为用户早期发现重症风险做出了贡献。其中,医院的覆盖活跃网点数量达到了276家,同比增长 527.3%;检测次数达到了24.2万,同比增长197.5%。基层医疗机构的覆盖活跃网点数达到了1,221家,同比增长1,271.9%;检测次数达到63.5万,同比增长640.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094116.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422691137","title":"鹰瞳科技发布2023年度业绩,营收增长79.5%,近视防控和海外业务成长迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2422691137","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422691137?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:06","pubTimestamp":1711551994,"startTime":"0","endTime":"0","summary":"格隆汇3月27日丨鹰瞳科技-B发布2023年度业绩,2023年,集团通过SaMD和健康风险评估解决方案共计服务了6.83百万病例,识别出 31,459例重大阳性案例,活跃服务网点数增长到5,671,同比增长139.2%,客户数量增长至673个,同比增长69.5%。2023年,集团将Airdoc-AIFUNDUS (1.0)销售给医院和基层医疗机构的网点数量和检测数量都有较大的增长。其中,医院的覆盖活跃网点数量达到了276家,同比增长 527.3%;检测次数达到了24.2万,同比增长197.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032723064787bcbee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032723064787bcbee5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913934","title":"鹰瞳科技-B(02251)发布2023年度业绩 收入2.04亿元 同比增加79.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913934","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422913934?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:22","pubTimestamp":1711549341,"startTime":"0","endTime":"0","summary":"智通财经APP讯,鹰瞳科技-B 发布截至2023年12月31日止年度业绩,该集团期内取得收入2.04亿元,同比增加79.46%;母公司拥有人应占亏损1.33亿元,同比收窄26.37%;每股基本亏损1.28元。2023年,集团通过SaMD和健康风险评估解决方案共计服务了6.83百万病例,识别出31459例重大阳性案例,活跃服务网点数增长到5671,同比增长139.2%,客户数量增长至673个,同比增长69.5%。其中,医院的覆盖活跃网点数量达到了276家,同比增长527.3%;检测次数达到了24.2万,同比增长197.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093982.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422467607","title":"鹰瞳科技-B盘中异动 早盘快速拉升5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422467607","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422467607?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:10","pubTimestamp":1711505408,"startTime":"0","endTime":"0","summary":"2024年03月27日早盘10时10分,鹰瞳科技-B股票出现异动,股价大幅拉升5.38%。资金方面,该股资金流入53.7474万港元,流出23.6802万港元。鹰瞳科技-B股票所在的医疗设备及用品行业中,整体跌幅为0.02%。其相关个股中,威高股份、鹰瞳科技-B、高视医疗涨幅较大,振幅较大的相关个股有威高股份、微创机器人-B、鹰瞳科技-B,振幅分别为9.68%、7.20%、6.84%。鹰瞳科技-B公司简介:北京鹰瞳科技发展股份有限公司是一家中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271010097a4f57f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271010097a4f57f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422659819","title":"鹰瞳科技-B(02251)上涨5.3%,报16.28元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422659819","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422659819?lang=zh_cn&edition=full","pubTime":"2024-03-26 15:23","pubTimestamp":1711437796,"startTime":"0","endTime":"0","summary":"3月26日,鹰瞳科技-B(02251)盘中上涨5.3%,截至15:23,报16.28元/股,成交337.69万元。北京鹰瞳科技发展股份有限公司主要业务是为慢性病的早期检测、辅助诊断及健康风险评估提供全面和多方位的人工智能解决方案,特别是在全球视网膜影像人工智能领域处于领先地位。公司的糖尿病视网膜病变辅助诊断软件是首个获得国家药监局第三类医疗器械证书的同类产品,已广泛应用于社区诊所、体检中心、保险公司、视光中心及药房等场所,为用户提供疾病辅助诊断及健康风险评估。截至2023年中报,鹰瞳科技-B营业总收入8250.2万元、净利润-3697.0万元。3月27日,鹰瞳科技-B将披露2023财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/26152339996133.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422065978","title":"鹰瞳科技-B盘中异动 股价大涨5.30%报16.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422065978","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422065978?lang=zh_cn&edition=full","pubTime":"2024-03-26 15:23","pubTimestamp":1711437792,"startTime":"0","endTime":"0","summary":"2024年03月26日下午盘15时23分,鹰瞳科技-B股票出现波动,股价大幅拉升5.30%。截至发稿,该股报16.280港元/股,成交量21.19万股,换手率0.40%,振幅4.66%。资金方面,该股资金流入168.389万港元,流出137.592万港元。鹰瞳科技-B股票所在的医疗设备及用品行业中,整体跌幅为0.16%。其相关个股中,鹰瞳科技-B、复锐医疗科技、华检医疗涨幅较大,振幅较大的相关个股有佳兆业健康、巨星医疗控股、紫元元,振幅分别为20.00%、19.35%、16.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261523127a4f1590&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261523127a4f1590&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422544846","title":"鹰瞳科技-B(02251)股价上升5.304%,现价港币$16.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2422544846","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422544846?lang=zh_cn&edition=full","pubTime":"2024-03-26 15:23","pubTimestamp":1711437780,"startTime":"0","endTime":"0","summary":"[上升股]鹰瞳科技-B(02251) 股价在下午03:23比前收市价上升5.304%,现股价为港币$16.28。至目前为止,今日最高价为$16.28,而最低价为$15.56。总成交量为21.19万股,总成交金额为港币$337.685万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403262644/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2420411070","title":"鹰瞳科技-B(02251)下跌7.01%,报14.32元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2420411070","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2420411070?lang=zh_cn&edition=full","pubTime":"2024-03-18 14:13","pubTimestamp":1710742419,"startTime":"0","endTime":"0","summary":"3月18日,鹰瞳科技-B(02251)盘中下跌7.01%,截至14:13,报14.32元/股,成交143.68万元。北京鹰瞳科技发展股份有限公司主要业务是为慢性病的早期检测、辅助诊断及健康风险评估提供全面和多方位的人工智能解决方案,特别是在全球视网膜影像人工智能领域处于领先地位。公司的糖尿病视网膜病变辅助诊断软件是首个获得国家药监局第三类医疗器械证书的同类产品,已广泛应用于社区诊所、体检中心、保险公司、视光中心及药房等场所,为用户提供疾病辅助诊断及健康风险评估。截至2023年中报,鹰瞳科技-B营业总收入8250.2万元、净利润-3697.0万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/18141339885043.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420560414","title":"鹰瞳科技-B盘中异动 大幅跳水7.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420560414","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420560414?lang=zh_cn&edition=full","pubTime":"2024-03-18 14:13","pubTimestamp":1710742417,"startTime":"0","endTime":"0","summary":"2024年03月18日下午盘14时13分,鹰瞳科技-B股票出现波动,股价急速下挫7.14%。鹰瞳科技-B股票所在的医疗设备及用品行业中,整体涨幅为0.08%。其相关个股中,康基医疗、先瑞达医疗-B、微泰医疗-B涨幅较大,振幅较大的相关个股有百心安-B、紫元元、巨星医疗控股,振幅分别为14.54%、11.88%、11.76%。鹰瞳科技-B公司简介:北京鹰瞳科技发展股份有限公司是一家中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318141338861df01b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318141338861df01b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420341423","title":"鹰瞳科技-B(02251)股价下跌7.273%,现价港币$14.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2420341423","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420341423?lang=zh_cn&edition=full","pubTime":"2024-03-18 14:13","pubTimestamp":1710742380,"startTime":"0","endTime":"0","summary":"[下跌股]鹰瞳科技-B(02251) 股价在下午02:13比前收市价下跌7.273%,现股价为港币$14.28。至目前为止,今日最高价为$15.72,而最低价为$14.28。总成交量为9.25万股,总成交金额为港币$143.681万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403181102/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2420496383","title":"“AI+医药”或成英伟达GTC重头戏!产业链投资飞速发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2420496383","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420496383?lang=zh_cn&edition=full","pubTime":"2024-03-18 10:16","pubTimestamp":1710728207,"startTime":"0","endTime":"0","summary":"即将于18日开幕的英伟达GTC大会上,有90场活动与医疗保健/生命科学相关——数目位居所有行业之首,超过了汽车、云服务、硬件/半导体等一众热门领域。她表示,英伟达的目标是为更多生物技术公司提供芯片、云基础设施与其他工具。单是2023年,英伟达就投资了8家药物发现初创公司。公司将大模型定位为新一代“医疗超级大脑”,目前应用已在C端及B端落地。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087595.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419763685","title":"鹰瞳科技-B(02251)股价上升8.738%,现价港币$15.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2419763685","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2419763685?lang=zh_cn&edition=full","pubTime":"2024-03-13 15:28","pubTimestamp":1710314880,"startTime":"0","endTime":"0","summary":"[上升股]鹰瞳科技-B(02251) 股价在下午03:28比前收市价上升8.738%,现股价为港币$15.68。至目前为止,今日最高价为$15.68,而最低价为$14.32。总成交量为16.14万股,总成交金额为港币$241.18万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403132013/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2419352475","title":"鹰瞳科技-B(02251)上涨5.27%,报15.18元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419352475","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419352475?lang=zh_cn&edition=full","pubTime":"2024-03-13 14:05","pubTimestamp":1710309945,"startTime":"0","endTime":"0","summary":"3月13日,鹰瞳科技-B(02251)盘中上涨5.27%,截至14:05,报15.18元/股,成交159.26万元。北京鹰瞳科技发展股份有限公司主要业务是为慢性病的早期检测、辅助诊断及健康风险评估提供全面和多方位的人工智能解决方案,特别是在全球视网膜影像人工智能领域处于领先地位。公司的糖尿病视网膜病变辅助诊断软件是首个获得国家药监局第三类医疗器械证书的同类产品,已广泛应用于社区诊所、体检中心、保险公司、视光中心及药房等场所,为用户提供疾病辅助诊断及健康风险评估。截至2023年中报,鹰瞳科技-B营业总收入8250.2万元、净利润-3697.0万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/13140539833018.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418309937","title":"鹰瞳科技-B获Mialkos Tomasz Jakub增持32.72万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2418309937","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2418309937?lang=zh_cn&edition=full","pubTime":"2024-03-12 16:01","pubTimestamp":1710230512,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示,3月8日,Mialkos Tomasz Jakub增持鹰瞳科技-B(02251)32.72万股,每股作价13.995港元,总金额约为457.92万港元。增持后最新持股数目为486.4万股,最新持股比例为9.1%。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-12/doc-inanaarf7716853.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-12/doc-inanaarf7716853.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418330808","title":"Mialkos Tomasz Jakub增持鹰瞳科技-B(02251)32.72万股 每股作价约14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418330808","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2418330808?lang=zh_cn&edition=full","pubTime":"2024-03-12 15:09","pubTimestamp":1710227350,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,3月8日,Mialkos Tomasz Jakub增持鹰瞳科技-B(02251)32.72万股,每股作价13.995港元,总金额约为457.92万港元。增持后最新持股数目为486.4万股,最新持股比例为9.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1085159.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1557},{"period":"3month","weight":0.362},{"period":"6month","weight":0.3486},{"period":"1year","weight":0.0842},{"period":"ytd","weight":0.362}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"鹰瞳Airdoc成立于2015年9月,总部在北京,截至2020年1月底,公司在北京、上海、广州、香港设立了子公司及研发中心。\n鹰瞳Airdoc是全球视网膜影像人工智能领域的领导者和先行者,公司基于视网膜影像人工智能识别的早期检测、辅助诊断及健康风险评估解决方案,通过视网膜影像、多模态数据分析以及人工智能深度学习算法,改善了慢性病传统的早期检测及诊断方式,在医疗机构和大健康场景中实现对慢性病的无创、精确、快速、高性价比且大规模的诊断及相关健康风险评估。\n2020年8月,鹰瞳Airdoc糖尿病视网膜病变眼底图像辅助诊断软件获国家药监局批准上市,在同类产品中首个获得国家药监局第三类医疗器械证书,并由此展开在国内医院的使用,协助及减轻医生的医学诊断工作。为解决未满足的医疗健康需求,公司开发了人工智能视网膜影像相关的丰富产品管线,已广泛应用于社区诊所、体检中心、保险公司、验光中心及药房等场所,为用户提供疾病辅助诊断及健康风险评估","exchange":"SEHK","name":"鹰瞳科技-B","nameEN":"AIRDOC-B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"鹰瞳科技-B(02251)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供鹰瞳科技-B(02251)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"鹰瞳科技-B,02251,鹰瞳科技-B股票,鹰瞳科技-B股票老虎,鹰瞳科技-B股票老虎国际,鹰瞳科技-B行情,鹰瞳科技-B股票行情,鹰瞳科技-B股价,鹰瞳科技-B股市,鹰瞳科技-B股票价格,鹰瞳科技-B股票交易,鹰瞳科技-B股票购买,鹰瞳科技-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"鹰瞳科技-B(02251)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供鹰瞳科技-B(02251)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}